Serum uric acid and cardiovascular mortality in chronic kidney disease: a meta-analysis

Abstract

BackgroundConflicting results have been reported from studies evaluating serum uric acid (SUA) levels as an independent risk factor for cardiovascular mortality in patients with chronic kidney disease (CKD).MethodsWe systematically searched MEDLINE, Web of Science, and bibliographies of retrieved articles to identify studies reporting on the association between SUA levels and cardiovascular mortality in patients with CKD. Random-effects models were used to calculate the pooled hazard ratios (HR) and corresponding 95% confidence intervals (CI).ResultsWe included 11 studies with an overall sample of 27,081 patients with CKD in this meta-analysis. By meta-analysis, restricted to 7 studies (n = 11,050), patients with the highest SUA were associated with an increased risk of cardiovascular mortality (HR 1.47, 95% CI 1.11–1.96) compared with patients with the lowest SUA. There was no indication of publication bias or significant heterogeneity (I2 = 40.4%; P = 0.109). Meta-analysis of 10 studies (n = 26,660) indicated that every 1 mg/dl increase in SUA levels increased a 12% risk in cardiovascular mortality (HR 1.12, 95% CI 1.02–1.24), with significant heterogeneity (I2 = 79.2%, P < 0.001).ConclusionsHigher SUA levels are associated with significantly increased risk of cardiovascular mortality in patients with CKD. More designed studies, especially randomized controlled trials, should be conducted to determine whether high SUA levels is a potentially modifiable risk factor for cardiovascular mortality in patients with CKD.Electronic supplementary materialThe online version of this article (10.1186/s12882-018-1143-7) contains supplementary material, which is available to authorized users.

The relationship between uric acid concentration and cardiovascular risk: Retrospective analysis of patients on hemodialysis

“…U naučnoj literaturi postoji veliki broj epidemioloških studija koje su ispitivale dijagnostičke karakteristike MK kao faktora rizika za KV bolesti kod bolesnika na HD (14). Međutim, ne postoji jasno slaganje u objavljenim rezultatima.…”

“…Akcenat svih ovih studija je bio na ispitivanju nezavisne povezanosti hiperurikemije i KV poremećaja, kao i ispitivanje njene potencijalne uzročnoposledične uloge u nastanku ovih bolesti. Postoje podaci koji pokazuju da sniženje koncentracije MK u krvi primenom farmakološke terapije, može imati pozitivne efekte u regulaciji krvnog pritiska, što ide u prilog potencijalne uloge hiperurikemije u nastanku KV morbiditeta (14). Međutim, nakon predstavljanja rezultata Framingam Heart studije iz 2003. godine, Američko udruženje za KV bolesti (American Heart Association, AHA) objavilo je da MK ne predstavlja nezavisni faktor rizika za koronarne sindrome jer nije nezavisna od hipertenzije (16).…”

Comparative Efficacy of the Course Injection Therapy with Iniectran or in Combination with Fermathron in Patients with Osteoarthritis of the Ankle Joints on the Background of Genytron Basic Application

“…Результаты последнего метаанализа с участием 27 081 пациента свидетельствуют, что ГУ у стра-дающих ХБП служит маркером риска сердечно-сосудистой смерти. Так, возрастание уровня МК на 1 мг/дл увеличивало риск сердечно-сосудистой смерти на 12% (ОР 1,12 (95% ДИ 1,02-1,24)) [12]. Остается дискутабельным вопрос о первопричине повышения МК, сопровождающего различные патологические процессы в организме, прежде всего поражение почек.…”

The relationship between serum uric acid concentration and cardiovascular risk factors in normotensivepostmenopausal women with dyslipidemia [pdf]

“…Aliment.,19(1), 123-131. http://dx.doi. org/10.17306/J.AFS.2020.0740 genetic factors (Luo et al, 2019). Causes of decreased excretion primarily include chronic kidney disease.…”